samedan logo

home > news > detailed info

Nemera’s preservative-free multi-dose eyedropper approved in Brazil for Aché’s NSAID’s and Dry Eye formulations


La Verpillière, France São Paulo, Brazil May 5, 2021 – Nemera is excited to announce that its multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON [1] (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat moderately severe pain and inflammation, usually after surgery.

Established for over 54 years, São Paulo based Aché is one of the largest domestic pharmaceutical company in Brazil. [2] The Ketorolac products will be the first of their kind commercialized in a preservative-free multi-dose format in the Brazilian market. These products will be available under prescription only.
Aché are also launching, in parallel, LAXIME [3] (Sodium Hyaluronate 0,15%) over the counter (OTC) solution for patients with Dry Eye Syndrome using Novelia®.

The Brazilian market presented a 4% growth ($ PMB IQVIA) in 2020 [4] with Dry Eye Disease experiencing double digit growth making it the no. 1 category in Brazil within the Ophthalmology Market [5]

“The entry of Aché in this segment represents an important reinforcement to the company's large portfolio. With the mission of enhancing people’s health and longevity, we understand that we also needed to work with ophthalmology to bring the quality and technology of Aché's products to this medical class. Our goal is not only to offer other options for the medical indication, but also to bring innovation to the Brazilian market in the coming years, and this partnership with Nemera will add great value to our products,” Marcelo Neri, Executive Director of Aché.

“It’s fantastic to see Aché bringing these products to the Brazilian market for the first time and expanding Novelia®’s global reach to improve patients’ lives in Latin America. With a growing number of patients suffering from chronic eye conditions, effective drug delivery and patient adherence are increasingly important. Combining the huge advantages of preservative-free formulations to avoid patient irritations with the ease of a multi-dose container system is a win-win and we are very proud to be partnering with Aché in this launch,” Denise Johnston, Vice President Global Sales at Nemera.

Nemera in figures:
  • 5 plants in Europe and USA
  • Insight Innovation Center with offices in Europe and the US
  • 2,600 employees
  • 30,000 sq. meters of manufacturing clean rooms
  • 150 engineers and experts in our Insight Innovation Center

Novelia® is a multidose closing tip dispensing system which avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment. A non-return valve system ensures that no contaminated liquid can be re-introduced into the container after the drop has been dispensed. The patented PureFlow® technology (a separate venting system with a silicone membrane) guarantees the intake of air which is free of contamination into the dispenser, after drop delivery.

With well over 200 market references worldwide, Novelia® is the patient’s prefered choice when it comes to preservative-free multi-dose eyedroppers [6] thanks to its patented blue tip to help in targeting the eye, precise and consistent drop size and patient friendly ergonomics including inititive screw-on cap and optimum squeeze force.

1. Clilon. Prescribing information. Aché Laboratórios Farmacêuticos S.A.

2. Annual Report. Aché Laboratórios Farmacêuticos S.A.

3. Laxime. Prescribing information. Aché Laboratórios Farmacêuticos S.A.

4. IQVIA. Dec/2020.

5. Kairos Web Brasil. Available at: March/2021.

6. Internal Report. Novelia. User study performed for Nemera by external party to understand the Novelia® market opportunities versus competitors”. 76% patients preferred Novelia® over other marketed devices. GfK report, Paris, France, (2015).
phone +33 4 74 94 06 54
email 20 avenue de la Gare, 38290 – La Verpillière, France
Print this page
Send to a friend
News and Press Releases

MBE for Boss of Pioneering Sustainable Pharma Packaging Firm

The Managing Director of a pioneering company that manufacturers sustainable packaging for the pharmaceutical industry has been awarded an MBE in the Queen’s Birthday Honours. Now Josie Morris, Managing Director of Staffordshire-based eco-packaging firm Woolcool, says she hopes the award will ‘help strengthen the growing status of sustainable alternatives, particularly natural materials, in pharma packaging’.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?


Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement